Madrigal Pharmaceuticals, Inc.
Conshohocken, PA
- UEI
- KA81N6BWY8L9
- CAGE
- 9TCT2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 200 Barr Harbor Dr # 200, Conshohocken, PA 19428, USA
- Website
- madrigalpharma.com
- Founded
- 2016
- Employees
- 51-250
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $65,309 |
| FY2025 | $2,951 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $65,309 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Rezdiffra 80 MG | Veterans Integrated Service Network 5 (VHA) | $29,686 | |
| Rezdiffra 80 MG | Veterans Integrated Service Network 5 (VHA) | $35,623 | |
| Rezdiffra 80 MG | Veterans Integrated Service Network 5 (VHA) | $2,951 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | Pasadena, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Melinta Therapeutics, LLC | Parsippany-Troy Hills, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| CSL Behring L.L.C. | King of Prussia, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Merz Pharmaceuticals, LLC | Raleigh, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Chartwell RX LLC | Congers, NY | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Madrigal Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer headquartered in Conshohocken, Pennsylvania, supplies REZDIFFRA (80 mg), a branded pharmaceutical product, to federal healthcare agencies as a prime contractor exclusively through General Services Administration Federal Supply Schedule and Blanket Purchase Agreement vehicles, with no subcontract footprint and no set-aside designations across its recent award portfolio.
Madrigal's customer base is entirely within the Department of Veterans Affairs ecosystem. The three distinct customer entities account for 100% of recent awards: the Department of Veterans Affairs National Acquisition Center (2 awards, $5.5 million combined potential value), the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 (2 awards, $250 thousand combined potential value), and the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 (3 awards, $68 thousand combined potential value). The National Acquisition Center dominates on dollar magnitude, while VISN 5 leads on award count, but both rankings are anchored exclusively to VA procurement channels. All seven awards fall under primary NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC code Drugs and Biologicals.
Madrigal holds two active indefinite delivery vehicles under the Pharmaceuticals and Drugs (FSS-61-IB) parent schedule. The first is a single-award BPA issued by the National Acquisition Center on March 5, 2025, with a ceiling of $455,079.50 and ultimate completion date of March 4, 2027, specifically for REZDIFFRA ordering. The second is a Federal Supply Schedule contract issued by VISN 12 on October 15, 2024, with a ceiling of $225,000 and completion date of October 14, 2029, covering drugs, pharmaceuticals, and hematology-related products. A prior $5 million single-award BPA from the National Acquisition Center, awarded July 25, 2024, was cancelled as of January 7, 2025. Recent delivery orders under these vehicles include a $29,685.90 order from VISN 5 on June 5, 2026 (performance in Carrollton, Texas), a $35,623.08 order from VISN 5 on April 3, 2026 (Carrollton, Texas), and a $2,951.08 order from VISN 5 on April 22, 2025 (Belle Isle, Florida). Activity has been modest and flat: three awards in 2024, two in 2025, two in 2026 through early June. Combined potential value across all awards sits at $5.8 million, with only $68 thousand obligated to date (1% of ceiling), reflecting the early-stage execution profile typical of recently awarded pharmaceutical supply agreements.
Quick answers
Is Madrigal Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Madrigal Pharmaceuticals, Inc.'s SAM.gov registration is active through August 4, 2027.
Which contract vehicles does Madrigal Pharmaceuticals, Inc. hold?
Madrigal Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Madrigal Pharmaceuticals, Inc. received in federal contracts?
Federal contracts obligated $2,951 to Madrigal Pharmaceuticals, Inc. in fiscal year 2025 and $68,260 in fiscal years 2023 through 2027.
What is Madrigal Pharmaceuticals, Inc.'s most recent federal award?
Madrigal Pharmaceuticals, Inc.'s most recent federal contract award is Rezdiffra 80 MG (36C24526N0629), from Veterans Integrated Service Network 5 (VHA), on June 5, 2026.
On GovTribe
See Madrigal Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors